In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Decision making for downgrading a cardiac resynchronization therapy device using cardiopulmonary exercise testing

Session Poster session 3

Speaker Madalena Coutinho Cruz

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome: Risk Factors and Risk Assessment
  • Session type : Poster Session
  • FP Number : P1530

Authors : M Coutinho Cruz (Lisbon,PT), A Abreu (Lisbon,PT), H Santa-Clara (Lisbon,PT), G Portugal (Lisbon,PT), I Rodrigues (Lisbon,PT), L Almeida-Morais (Lisbon,PT), AS Delgado (Lisbon,PT), P Silva-Cunha (Lisbon,PT), M Mota-Carmo (Lisbon,PT), R Cruz-Ferreira (Lisbon,PT), M Martins-Oliveira (Lisbon,PT)


M Coutinho Cruz1 , A Abreu1 , H Santa-Clara2 , G Portugal1 , I Rodrigues1 , L Almeida-Morais1 , AS Delgado1 , P Silva-Cunha1 , M Mota-Carmo3 , R Cruz-Ferreira1 , M Martins-Oliveira1 , 1Hospital de Santa Marta, Serviço de Cardiologia - Lisbon - Portugal , 2Instituto Superior TǸcnico - Lisbon - Portugal , 3NOVA Medical School - Lisbon - Portugal ,


Background: Heart failure (HF) patients (pts) with an indication for cardiac resynchronization therapy (CRT) often also have an indication for an implantable cardioverter-defibrillator (ICD) to prevent sudden cardiac death. However, for pts with satisfying response to CRT at the time of device generator replacement, this indication may no longer be accurate. There are currently no optimal aids to identify pts who will no longer benefit from CRT-ICD and where downgrading CRT-P is appropriate.

Aim: To determine predictors of sustained ventricular arrhythmias (SVA) in pts with good response to CRT.

Methods: Prospective cohort study of HF pts with reduced ejection fraction submitted to CRT-ICD. NYHA class, blood analysis, cardiopulmonary exercise testing and echocardiography were performed before and 3-6 months after CRT. In pts with no SVA prior to CRT (primary prevention) and with left ventricular ejection fraction (LVEF) > 35% 3-6 months after CRT, predictors of SVA were determined using regression analysis. Calibration of a score was assessed by Hosmer-Lemeshow test and discrimination, sensitivity, specificity and likelihood ratio by the area under the receiver operating curves (AUC).

Results: Of the 114 pts analyzed (70±14 years, 69.2% men, 29.1% ischemic etiology, 73.1% baseline NYHA III-IV, baseline LVEF 27%±11%), 69 (60.5%) had LVEF > 35% 3-6 months after CRT. In this population, 14 pts (20.3%) experienced a SVA during a mean follow-up of 38.3 months. 8 pts (12.0%) suffered inappropriate device therapies, adding up to a total of 35 episodes. Furthermore, 11 pts (15,9%) were submitted to generator replacement during follow-up. SVA were associated with troponin I (OR 1.427x10^22 95% CI 27.636-7.372x10^42 p 0.036), high-density lipoprotein (OR 0.957 95% CI 0.912-1.004 p 0.071), VEVCO2 slope (OR 1.097 95% CI 1.021-1.178 p 0.011), systolic blood pressure (OR 0.974 95% CI 0.974-1.001 p 0.062) and end-diastolic left ventricular volume (OR 1.006 95% CI 1.000-1.011 p 0.046). In the multivariate analysis, VEVCO2 slope was the only independent predictor of SVA (OR 1.156 95% CI 1.042-1.283 p 0.006). As a score to predict SVA, VEVCO2 slope showed good calibration and good discrimination with an AUC of 0.70. The ideal cut-off value of VEVCO2 slope to exclude SVA during follow-up is 24.35 (negative likelihood ratio 0.5).

Conclusion: The incidence of SVA in pts with adequate response to CRT is relatively high. On the other hand, inappropriate therapies are not an uncommon event. Cardiopulmonary exercise testing with assessment of VEVCO2 slope can be used as a widely accessible method with low cost to recognize pts who will no longer benefit from CRT-ICD (and to whom it may cause harm due to inappropriate therapies) and where downgrading CRT-P is suitable.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are